One Shot to Rewrite Your DNA: The CRISPR Therapy Knocking on the FDA's Door
The FDA just accepted Intellia's application for the first-ever in vivo CRISPR gene editing therapy and put it on Priority Review. If lonvo-z gets approved by its March 2027 deadline, it won't just help patients with hereditary angioedema; it'll prove we can cure genetic diseases with a single infusion.
The Gene Editing Moment We've Been Waiting For
Imagine getting a single IV infusion that rewrites a faulty gene in your liver, then disappears. No refills. No monthly injections. No lifelong prescriptions. Just one treatment, and the underlying genetic mistake that's been making you sick gets permanently corrected at the DNA level.
That's what Intellia Therapeutics is betting on. And the FDA just signaled it's taking the bet seriously.
The agency accepted Intellia's application for lonvoguran ziclumeran (mercifully nicknamed "lonvo-z"), granting it Priority Review for hereditary angioedema (HAE). The decision date: March 10, 2027. If approved, lonvo-z would become the first-ever in vivo CRISPR gene editing therapy to reach the U.S. market.
That distinction matters more than you might think.
Why "In Vivo" Changes Everything
Let's rewind. The FDA approved the first CRISPR-based therapy, Casgevy, back in December 2023 for sickle cell disease. It was a genuine landmark. But Casgevy is what scientists call an ex vivo therapy: doctors pull cells out of your body, edit them in a lab, and put them back in. Think of it like taking your car to the shop for an engine rebuild.
Lonvo-z works completely differently. It's in vivo, meaning the editing happens inside your body. Intellia packages the CRISPR components (Cas9 instructions plus a molecular GPS guide) into tiny fat bubbles called lipid nanoparticles. You get an IV drip. The nanoparticles find your liver cells. The CRISPR machinery makes a precise DNA cut, disabling the problem gene. Then the editing tools break down and clear out, leaving behind a permanent genetic fix.
It's closer to sending a mechanic to your house who fixes the engine while you're still driving the car, then quietly leaves.
The fact that the FDA is comfortable putting this on a Priority Review timeline (six months instead of the standard ten) tells you something important about how regulators now view gene editing. It's not a science experiment anymore. It's a real therapeutic option competing on the same fast track as conventional drugs.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Disease: Rare, Painful, and Poorly Controlled
Hereditary angioedema is one of those rare diseases that sounds manageable until you actually learn what it does. HAE causes unpredictable episodes of severe swelling in the face, throat, gut, and extremities. Throat attacks can be life-threatening. Episodes can last days. And they can strike without warning.
Patients currently manage the condition with chronic preventive therapies, many of which require regular injections. The treatments work reasonably well for some people, but they don't fix the root cause. Stop taking them, and the attacks come back.
Lonvo-z aims to change that math entirely. By editing the KLKB1 gene in liver cells (the gene responsible for producing a protein involved in the swelling cascade), a single dose could offer lasting protection.
The Data That Got Intellia to the FDA's Doorstep
The application leans on results from Intellia's Phase 3 HAELO trial, and the numbers are striking. Patients who received lonvo-z saw an 87% reduction in average monthly HAE attacks compared to placebo over a six-month evaluation period. Even more impressive: 62% of treated patients were completely attack-free and therapy-free, versus just 11% in the placebo group.
On the safety front, the most common side effects were infusion-related reactions, headaches, and fatigue. All reported events through the data cutoff were mild or moderate, with no serious adverse events in the lonvo-z arm.
For a one-time treatment, those are compelling numbers. And the FDA apparently agrees: the agency told Intellia it is not currently planning to hold an advisory committee meeting for the application. That's generally read as a sign of regulatory confidence, since advisory committees are often convened when there are tricky scientific questions the FDA wants outside experts to weigh in on.
The Bigger Picture: CRISPR Goes Mainstream
Approving lonvo-z wouldn't just matter for HAE patients. It would validate an entire category of medicine.
Since Casgevy's approval, the gene editing field has been waiting for someone to prove that in vivo CRISPR can clear the same regulatory bar. Ex vivo editing is powerful, but it's limited to diseases where you can practically remove and return cells (mostly blood disorders). In vivo editing, if it works and scales, opens the door to treating diseases in organs you can't easily take apart and reassemble: the liver, the brain, the heart.
Intellia already has a second in vivo program, NTLA-2001, targeting hereditary transthyretin amyloidosis (a disease where misfolded proteins damage the heart and nerves). Early data from that program showed a single dose could reduce the problem protein (transthyretin) by 87% within 28 days, with the effect sustained for months. It's a different disease and a different stage of development, but it reinforces the core premise: one infusion, lasting results.
What Wall Street Thinks (and Why It's Complicated)
Despite the regulatory momentum, analyst sentiment on Intellia is surprisingly mixed. Price targets range from a bearish $5 (JPMorgan, Underweight) all the way up to around $60 from Buy-rated analysts citing lonvo-z progress and strong cash runway. The consensus hovers in the low-to-mid $20s.
Why the spread? Part of it is just the nature of pre-revenue biotech: until a product is approved and generating sales, valuation depends heavily on assumptions about market size, pricing, and competition. HAE is a real market, but it's a rare disease. The bigger commercial opportunity likely hinges on whether Intellia can replicate this success across multiple indications.
There's also the question of durability. Lonvo-z's Phase 3 data covers six months of follow-up. For a therapy positioned as a one-time cure, regulators and payers will eventually want to see longer-term evidence that the edit holds. So far, so good; but "so far" is doing some heavy lifting in that sentence.
The March 2027 Countdown
With a PDUFA date of March 10, 2027, the clock is now ticking. No advisory committee is currently planned. The Phase 3 data is clean. The safety profile looks manageable. On paper, the path to approval is about as smooth as it gets in biotech.
But biotech has a habit of humbling people who get too comfortable. Between now and March, Intellia needs the FDA review to proceed without complications, and investors need to decide whether the stock's current valuation already prices in the good news.
What's not in doubt is the significance of the moment. If lonvo-z crosses the finish line, it won't just be a new drug for a rare disease. It'll be proof that we can send molecular scissors into a living human body, make a precise edit to their DNA, and walk away with a cure.
That's not science fiction anymore. It's a PDUFA date on a calendar.
Clinical & Regulatory4 min read
Roivant's Lung Drug Just Posted Data That Has Wall Street Buzzing
Roivant's inhaled lung drug just posted Phase 2 data strong enough to send the stock up 20% in a day. One analyst thinks it could be a $10 billion-a-year drug. Here's why the numbers have Wall Street losing its mind.
